Gowling WLG wins Impact Case of the Year at LMG European Life Sciences Awards

Gowling WLG's Life Sciences team has received the award for 'Impact Case of the Year' at last night's LMG European Life Sciences Awards 2023.

The award recognises the team's work in the 'Neurim Pharmaceuticals and Flynn Pharma v Generics and Viatris Healthcare' case, led by partner Paul Inman and principal associate Christopher Freeth. The work also gained profile with a win at the Managing IP EMEA Awards 2023, announced last month.

Now in its 11^th year, the LMG Life Sciences Awards is well-established and brings together Europe's legal community to celebrate key successes across the industry. The awards are presented to firms, individuals and companies behind the most innovative and challenging life sciences work of the past year, as well as those driving the international market.

The 2023 awards were announced at a gala dinner in London last night and celebrated winners across a wide range of categories.

Gowling WLG's global life sciences group combines the expertise of more than 150 legal professionals to advise companies on the unique challenges they face throughout their life cycles. A top-ranked firm in Chambers UK (2023), it is well-recognised for its "complex license, research and collaboration agreements", often spanning multiple jurisdictions, as well as its "excellent" work on corporate and investment transactions and handling of life sciences disputes.